ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bristol-Myers Squibb and Pfizer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Bristol-Myers SquibbPfizer
studies on the registry2,1844,072
open to participants now156146
phase 3 studies under way8299
reach primary completion within a year6891
programswith a study of their own in two years58+9 named only91+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBristol-Myers SquibbPfizer
Phase 1

Bristol-Myers Squibb: 17 of its 58 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

29%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%
Phase 2

Bristol-Myers Squibb: 18 of its 58 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 13 more — sign in to see them all

31%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
Phase 3

Bristol-Myers Squibb: 16 of its 58 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
Approved, new studies

Bristol-Myers Squibb: 7 of its 58 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bristol-Myers Squibb23 readouts · 8 phase 3

Bristol-Myers Squibb, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. deucravacitinibapproved, new study · Nov 18 · NCT05946941
  2. trospiumapproved, new study · Nov 24 · NCT06585787
  3. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. trospium chlorideapproved, new study · Dec 3 · NCT07204418
  3. navlimetostatphase 3 · Dec 5 · NCT07777133
  4. delocamtenphase 2 · Dec 14 · NCT06122779
  5. golcadomidephase 3 · Dec 14 · NCT07763418

and 3 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836
··

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10 · Carcinoma, Non-Small-Cell Lung
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 24 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBristol-Myers SquibbPfizer
Carcinoma, Non-Small-Cell Lungboth · compare here

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 12 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 7 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 4 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bristol-Myers Squibb in Colorectal Neoplasms: 5 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Anti-CEACAM5 Antibody-drug Conjugate BMS-986490phase 2
  4. BMS-986488phase 1
  5. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Obesityboth · compare here

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Small Cell Lung Carcinomaboth · compare here

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Multiple Myelomaboth · compare here

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Alzheimer Diseaseboth · compare here

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

COVID-19both · compare here

Bristol-Myers Squibb in COVID-19: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of COVID-19 in search

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Melanomaboth · compare here

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Lupus Erythematosus, Systemicboth · compare here

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Arthritis, Rheumatoidboth · compare here

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Neoplasmsboth · compare here

Bristol-Myers Squibb in Neoplasms: 3 programs

  1. BMS-986500phase 1
  2. Digoxinphase 1
  3. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Pfizer in Neoplasms: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Show all 24

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bristol-Myers Squibb 33 of 58 · Pfizer 67 of 91 programs (33 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9, Pfizer: 9).